ESR1 and breast carcinoma: As shown in Table 2, multivariate logistic regression analyses indicated that ESR1 mutation-positive breast cancer cases were more likely to have ever used OCs (OR = 1.72, 95% CI = 0.66 to 4.44), but this result was not statistically significant.